Investing.com - Financial Markets Worldwide
💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Glaukos iStent lowered IOP 35% in open-angle glaucoma patients

Published 06/21/2017, 07:51 AM
© Reuters. Glaukos iStent lowered IOP 35% in open-angle glaucoma patients
GKOS
-
  • Results from an international study assessing Glaukos' (NYSE:GKOS) iStent, combined with topical travoprost (Alcon's Travatan), for the treatment of open-angle glaucoma showed a 35% reduction in average intraocular pressure (IOP) after 18 months of follow-up. The results were recently published in journal Clinical & Experimental Ophthalmology.
  • Additional results from the 53-subject study: at month 12, 91% of eyes achieved at least a 20% decrease in IOP with the reduction of one medication and 100% of eyes achieved IOP of no more than 18 mm Hg (normal range is 10 - 21 mm Hg) with the reduction of one medication.
  • The FDA approved iStent in 2012.
  • The company's next-generation iStent Inject device is designed to deploy two stents into separate trabecular meshwork locations in the eye to enhance IOP reduction and make it easier to implant.
  • Now read: Myomo (MYO) Presents At 2017 Marcum Microcap Conference - Slideshow


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.